



Taro Pharmaceuticals U.S.A., Inc.  
Attention: Avraham Yacobi, Ph.D.  
5 Skyline Drive, Suite 3  
Hawthorne, NY 10532-2155

APR 14 2003

Docket No. 02P-0498/CP1

Dear Dr. Yacobi:

This is in response to your petition filed on November 26, 2002, and your amendment dated March 17, 2003, requesting permission to file an Abbreviated New Drug Application (ANDA) for the following drug product: Warfarin Sodium Tablets USP, 0.5 mg. The reference listed drug product to which you refer in your petition is Coumadin® (Warfarin Sodium) Tablets, 2 mg, approved under NDA 09-218 held by Bristol-Myers Squibb Pharma Co. In addition, you also refer to several other strengths in support of your petition. Please be advised that, pursuant to 21 CFR 314.93, the petitioner shall identify a listed drug as the drug of reference for requested changes.

Your request involves a change in strength from that of the listed drug product (i.e., from 1 mg tablets to 0.5 mg tablets). The change you request is the type of change that is authorized under the Federal Food, Drug, and Cosmetic Act (Act).

We have reviewed your petition under Section 505(j)(2)(C) of the Act and have determined that it is approved. This letter represents the Food and Drug Administration's (FDA) determination that an ANDA may be submitted for the above-referenced drug product.

Under Section 505(j)(2)(C)(i) of the Act, the FDA must approve a petition seeking a strength that differs from the strength of the listed drug product unless it finds that investigations must be conducted to show the safety and effectiveness of the differing strength.

The FDA finds that the change in strength for the specific proposed drug product does not pose questions of safety or effectiveness because the uses and route of administration of the proposed drug product are the same as that of the listed drug product. The approved labeling for the listed drug indicates that doses of warfarin sodium must be individualized and adjusted for each patient based upon the patient's PT/INR response to the drug and that certain patient populations require lower initiation and maintenance doses of warfarin sodium. Additionally, the proposed lower dose (warfarin sodium, 0.5 mg) may also be useful for dosage adjustment. The FDA concludes, therefore, that investigations are not necessary in this instance. In addition, if shown to meet bioavailability requirements, the proposed drug product can be expected to have the same

02P-0498

PAV 1

02P-0498/CP1  
Taro Pharmaceuticals U.S.A., Inc

therapeutic effect as the listed reference drug product.

The approval of this petition to allow an ANDA to be submitted for the above-referenced drug product does not mean that the FDA has determined that an ANDA will be approved for the drug product. The determination of whether an ANDA will be approved is not made until the ANDA itself is submitted and reviewed by the FDA.

To permit review of your ANDA submission, you must submit all information required under Sections 505(j)(2)(A) and (B) of the Act. To be approved, the drug product will, among other things, be required to meet current bioavailability requirements under Section 505(j)(2)(A)(iv) of the Act. For your information, requests for waivers of *in vivo* bioequivalence are not evaluated as part of the petition process. Requests for waivers are evaluated when the ANDA is submitted. We suggest that you submit your protocol for this drug product to the Office of Generic Drugs, Division of Bioequivalence, prior to the submission of your ANDA. During the review of your application, the FDA may require the submission of additional information.

The listed drug product to which you refer in your ANDA must be the one upon which you based this petition. In addition, you should refer in your ANDA to the appropriate petition docket number cited above, and include a copy of this letter in the ANDA submission.

A copy of this letter approving your petition will be placed on public display in the Dockets Management Branch, Room 1061, Mail Stop HFA-305, 5630 Fishers Lane, Rockville, MD 20852.

Sincerely yours,



Gary J. Buehler  
Director  
Office of Generic Drugs  
Center for Drug Evaluation and Research